BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 31451895)

  • 1. Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.
    Fischer AK; Pham DL; Bösmüller H; Lengerke C; Wagner P; Bachmann C; Beschorner C; Perner S; Kommoss S; Fend F; Staebler A
    Virchows Arch; 2019 Oct; 475(4):479-488. PubMed ID: 31451895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract.
    Kitamura H; Torigoe T; Hirohashi Y; Asanuma H; Inoue R; Nishida S; Tanaka T; Fukuta F; Masumori N; Sato N; Tsukamoto T
    Mod Pathol; 2013 Jan; 26(1):117-24. PubMed ID: 22899292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesothelin Expression Is Not Associated with the Presence of Cancer Stem Cell Markers SOX2 and ALDH1 in Ovarian Cancer.
    Nunes M; Pacheco F; Coelho R; Leitão D; Ricardo S; David L
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expansion of secretory cells in the fallopian tubal epithelium in the early stages of the pathogenesis of ovarian serous carcinomas].
    Asaturova AV; Ezhova LS; Faizullina NM; Adamyan LV; Khabas GN; Sannikova MV
    Arkh Patol; 2017; 79(3):10-18. PubMed ID: 28631711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.
    Kuroda T; Hirohashi Y; Torigoe T; Yasuda K; Takahashi A; Asanuma H; Morita R; Mariya T; Asano T; Mizuuchi M; Saito T; Sato N
    PLoS One; 2013; 8(6):e65158. PubMed ID: 23762304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2.
    Matsika A; Srinivasan B; Day C; Mader SA; Kiernan DM; Broomfield A; Fu J; Hooper JD; Kench JG; Samaratunga H
    Pathology; 2015 Dec; 47(7):622-8. PubMed ID: 26517640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.
    Hasby EA
    Tumour Biol; 2016 Apr; 37(4):4889-900. PubMed ID: 26526579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
    Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
    [No Abstract]   [Full Text] [Related]  

  • 11. Correlation of ALDH1, CD44, OCT4 and SOX2 in tongue squamous cell carcinoma and their association with disease progression and prognosis.
    Huang CF; Xu XR; Wu TF; Sun ZJ; Zhang WF
    J Oral Pathol Med; 2014 Aug; 43(7):492-8. PubMed ID: 24450601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 13. SOX2 expression and prognostic significance in ovarian carcinoma.
    Pham DL; Scheble V; Bareiss P; Fischer A; Beschorner C; Adam A; Bachmann C; Neubauer H; Boesmueller H; Kanz L; Wallwiener D; Fend F; Lengerke C; Perner S; Fehm T; Staebler A
    Int J Gynecol Pathol; 2013 Jul; 32(4):358-67. PubMed ID: 23722508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX2 and ALDH1 as Predictors of Operable Breast Cancer.
    Shima H; Kutomi G; Satomi F; Maeda H; Hirohashi Y; Hasegawa T; Mori M; Torigoe T; Takemasa I
    Anticancer Res; 2016 Jun; 36(6):2945-53. PubMed ID: 27272809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of ALDH1 and SOX2 diffuse staining pattern of oral squamous cell carcinomas correlates to lymph node metastasis.
    Michifuri Y; Hirohashi Y; Torigoe T; Miyazaki A; Kobayashi J; Sasaki T; Fujino J; Asanuma H; Tamura Y; Nakamori K; Hasegawa T; Hiratsuka H; Sato N
    Pathol Int; 2012 Oct; 62(10):684-9. PubMed ID: 23005595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
    Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
    Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
    Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
    Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.